Until recently, consumerism in the U.S. healthcare industry has moved slowly. However, several converging forces are likely to change the situation soon and result in a more dynamic market. Higher deductibles and copayments, greater transparency into provider performance and costs, and the rise of network narrowing and provider-led health plans are prodding patients to become more involved in healthcare decision making than ever before.
As yet, most payors and providers have comparatively little data to assess how consumerism is likely to affect them. As a consequence, they can neither confirm nor refute a number of assumptions about healthcare consumerism that are often stated as fact.
Austin, TX’s Stellarray aims to democratize access to radiography.
Right now, imaging machines like CT scanners are large, bulky, and expensive, and usually housed in major medical centers. “We’re taking an open architecture approach to radiography,” says Mark Eaton, Stellarray’s founder and CEO. “We want to make it affordable and portable.”
Stellarray has developed imaging technology that, Eaton says, would more cheaply and easily perform functions like mammograms or irradiating blood. Think of it as flat-screen panels meet laser-like X-rays.
Cómo extraer valor médico más allá del caos que generan los millones de datos sobre enfermedades y fármacos en internet, no siempre fiables o incluso peligrosos, es el objetivo de un proyecto europeo de "Big Data" sobre salud, del que informa su coordinador, Allan Hanbury, en una entrevista a Efefuturo.
For better or worse, companies in seemingly every industry are starting to connect devices to the Internet, the idea being that data from the machines can provide fresh and useful insights.
A new study shows people’s bodies react to the same foods in very different ways, adding to a growing body of research that suggests people may be better able to achieve weight loss if their diet was tailored to them, rather than following general advice about foods to eat and avoid.
Año tras año, parece que este evento, la feria anual más relevante del sector sanitario, se supera a sí mismo recibiendo cada vez más visitantes y expositores de cada vez más partes del mundo. Más de 130.000 visitantes especia-listas de más de 120 nacionalidades y alrededor de 5.500 expositores de 70 naciones repartidos entre MEDICA y COMPAMED, entre el 16 y el 19 de Noviembre de 2015 en el Messe Düsseldorf, Alemania. Un año más, empresas de MONDRAGON han estado presentes en la feria: BEXEN Cardio, BEXEN Medical, Cikautxo Medical y ULMA Packaging.
Most companies make a conscious and deliberate decision to embrace digitization and the information revolution. Yet the role of big data in medicine seems almost to compel organizations to become involved. In this interview, Dr. Eric Schadt, the founding director of the Icahn Institute for Genomics and Multiscale Biology at New York’s Mount Sinai Health System, tells McKinsey’s Sastry Chilukuri how data-driven approaches to research can help patients, in what ways technology has the potential to transform medicine and the healthcare system, and how the Icahn Institute is building its talent base. An edited transcript of Schadt’s remarks follows.
In 1980, the world collectively shed not a single tear upon hearing that the scourge of smallpox would likely never take another life. A gargantuan global effort had eradicated the disease in the open (though the virus still survives in government labs). Now it looks as if humanity will be able to close the book on polio, another terrible infectious disease that has wreaked havoc throughout history.
Pfizer está en negociaciones avanzadas para adquirir Allergan, en la que sería la mayor operación de la historia de la industria farmacéutica.
Pfizer pagaría cada acción de Allergan entre 370 y 380 dólares, según informa Bloomberg citando fuentes cercanas a la negociación. Esto implica valorar la compañía productora de Botox unos 150.000 millones de dólares, lo que transforma esta operación en la mayor nunca realizada en el sector farmacéutico.
El acuerdo podría ser anunciado el próximo lunes, según afirma la agencia citando dos fuentes. Sin embargo, matiza que el nuevo reglamento del Tesoro sobre la fiscalidad de las fusiones, presentado ayer, podría retrasar la firma o provocar algunos cambios en los términos de la transacción.
